Akero Therapeutics will present new 96-week Phase 2b data for efruxifermin at the AASLD Liver Meeting 2025, including two oral presentations from the SYMMETRY trial in compensated cirrhosis (F4) due to MASH and an AI-powered histology analysis from the HARMONY trial in pre-cirrhotic disease (F2–F3). The SYMMETRY readouts highlight improvements in non-invasive fibrosis measures and markers of portal hypertension assessed by Baveno VII criteria, while the HARMONY poster examines efruxifermin-driven changes in liver microarchitecture using digital pathology. With three Phase 3 SYNCHRONY studies already underway across F2–F4 and a real-world evidence program in market-like settings, Akero is moving to frame efruxifermin not just as a histology drug, but as a potential outcomes-modifying therapy in cirrhosis.
The strategic question is whether these signals can accelerate the shift from biopsy-defined surrogates to a more clinically anchored evidence package built on non-invasive tests and portal hypertension biology. In a post-approval landscape defined by Madrigal’s first-to-market entry for F2–F3 and rising GLP-1 use that reduces liver fat without addressing fibrosis directly, differentiation will hinge on convincing regulators and payers that an antifibrotic can demonstrably change the trajectory of cirrhosis. Improvement on Baveno VII criteria, which operationalize risk of clinically significant portal hypertension using elastography and platelets, aims squarely at that bar.
For patients with compensated cirrhosis, the stakes are immediate. There is still no approved MASH therapy for F4, and preventing progression to decompensation remains the core value proposition. If efruxifermin can reduce portal pressure risk and show consistent regression signals across non-invasive modalities over 96 weeks, hepatologists gain an intervention aligned with how they already monitor these patients. For payers, the use of standardized, scalable non-invasive tests creates a basis for utilization management and continuation rules without repeated biopsies, and it opens the door to outcomes-based contracts anchored to decompensation rates or Baveno transitions. For HCPs across endocrine and cardiometabolic clinics where MASLD is prevalent, the HARMONY digital histology work underscores a growing need to harmonize diagnostic pathways, integrate elastography and labs, and understand how metabolic improvement translates into structural liver change.
Competitive dynamics are intensifying. FGF21 analogs remain a focal class, with multiple late-stage programs vying to pair robust hepatic biology with cardiometabolic benefits. Digital pathology and AI-derived microarchitecture metrics are gaining traction to mitigate biopsy variability and increase sensitivity to treatment effects, a trend regulators and HTA bodies are watching as they refine evidentiary standards. The SYMMETRY emphasis on portal hypertension aligns with a broader pivot toward clinically meaningful endpoints that matter in hospital budgets, transplant queues, and payer actuarial models. The SYNCHRONY real-world study suggests Akero is preparing for an access environment that will reward demonstrable reduction in advanced liver care costs.
The near-term hinge is whether the Phase 3 outcomes study in cirrhosis can translate these 96-week signals into hard clinical benefit and whether agencies will accept composites involving Baveno VII and other non-invasive markers to support broader labeling. As metabolic therapeutics strain formularies and obesity drugs reshape care pathways, the cirrhosis segment offers a clear unmet-need beachhead. The question for Commercial and Medical leaders is whether efruxifermin can turn conference-stage biomarker momentum into an outcomes narrative compelling enough to reset payer expectations — and, if it does, how quickly competitors will pivot their endpoints and evidence generation to match it.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
